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Abstract
Background: The diagnostic criteria for growth hormone (GH) deficiency (GHD) in adolescents
and young adults are not yet clearly established.
We evaluated the factors influencing the GH peak and plasma insulin-like growth factor (IGF) I in
order to determine the cut-off limits for the diagnosis of GHD during the transition period.
Methods: 21 patients treated for GHD due to pituitary stalk interruption syndrome at 5.7 ± 4.1
years were reevaluated at 16.0 ± 1.8 years, 0.6 ± 0.6 years after the end of GH treatment. Group
1 had isolated GHD (n = 9) and group 2 had multiple pituitary deficiencies (n = 12), including
deficiencies of thyroid stimulating (n = 12), adrenocorticotropin (n = 8) and gonadotropin (n = 9)
hormones.
Results: At diagnosis, group 1 had a greater pituitary height (2.8 ± 1.2 vs 1.6 ± 1.1 mm, P = 0.03)
and GH peak (3.8 ± 1.9 vs 1.6 ± 1.5 ng/ml, P < 0.02) than did group 2.
At last evaluation, group 1 had greater GH peak (3.9 ± 1.9 vs 0.2 ± 0.4 ng/ml, P = 0.0001) and plasma
IGF I (211 ± 88 vs 78 ± 69 ng/ml, P < 0.002) than did group 2. No group 1 and 9 group 2 patients
had an undetectable GH peak, while the 3 others had GH peak below 1 ng/ml.
The GH peak decreased between diagnosis and last evaluation only in group 2 (P < 0.008).
Conclusion:  The GH peak response to pharmacological stimulation and the plasma IGF I
concentration in young adults with GHD of childhood onset depend on the presence of additional
pituitary deficiencies, reflecting a more severe defect of the hypothalamic-pituitary axis. The sex
steroids cannot increase the IGF I if the GH secretion is zero.
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Background
The diagnostic criteria for growth hormone (GH) defi-
ciency (GHD) in adolescents and young adults, defined as
the transition period, are not yet clearly established.
Severe GHD in adults is defined by a peak GH response to
hypoglycemia of less than 3 ng/ml [1], while a limit of 5
ng/ml in response to a stimulation test has been proposed
for adolescents in transition to adult care [2].
The factors reported to influence the GH peak and plasma
insulin-like growth factor (IGF) I concentration in GHD
are the age at onset (childhood or adulthood) [3] and the
etiology (hypothalamic-pituitary lesion, cranial irradia-
tion or idiopathic) [4]. However, the effect of the sponta-
neous pubertal increase in sex steroids at puberty on these
two parameters in GH-deficient patients has not been
clearly evaluated [2].
We analysed longitudinally 21 patients with pituitary
stalk interruption syndrome (PSIS). We classified them as
isolated GHD and multiple pituitary deficiencies. We
compared the GH stimulated peak and plasma IGF I con-
centrations of the two groups and at diagnosis before
puberty and after their growth had ended. Our objective
was to evaluate the factors influencing the GH peak and
plasma IGF I in order to determine the cut-off limits for
the diagnosis of GHD during the transition period.
Methods
Patients
This retrospective longitudinal study included 21 consec-
utive patients (13 boys and 8 girls) monitored by one of
us (R Brauner) in a tertiary university pediatric hospital.
All had GHD of prepubertal onset due to PSIS, had
reached their adult height and were reevaluated for their
GH secretion after the end of GH treatment. The criterion
for diagnosing GHD during childhood was a GH peak
response (maximal GH concentration) of less than 7 ng/
ml after 2 stimulation tests, excluding the GH-releasing
hormone (GHRH) test. Other features suggesting GHD
were microphallus (6 boys), hypoglycemia (n = 8) and
other hypothalamic-pituitary deficiencies (n = 12).
PSIS was diagnosed on the basis of no visible pituitary
stalk, no normal posterior lobe hypersignal in the sella
turcica, and the presence of a hyperintense nodule in the
region of the infundibular recess of the third ventricle [5].
The patients were divided into two groups: group 1 with
isolated GHD (n = 9) and group 2 with multiple pituitary
deficiencies (n = 12), including deficiencies of thyroid
stimulating (n = 12), adrenocorticotropin (n = 8) and
gonadotropin (n = 9) hormones.
The ages were 5.7 ± 4.1 years at diagnosis and 16.0 ± 1.8
years at the last GH evaluation, 0.6 ± 0.6 years after the
end of GH treatment.
Protocol
The patients and their parents were informed that the
evaluation would be performed to measure GH secretion,
to adjust the replacement therapy (other than GH), and to
prepare for the transfer of the follow-up to adult depart-
ments. They gave their consent for this evaluation. All
patients underwent 3 stimulation tests, 2 at diagnosis
before GH treatment and the third after treatment had
ended. Each evaluation was performed in a single morn-
ing with patients in a fasting state, and included a physical
examination plus measurements of height and weight.
Before treatment, at least 1/2 stimulations used arginine
insulin (n = 15) or glucagon (n = 5), except for 1 patient
who was stimulated with ornithine. The larger peak was
used for statistical analysis. GH therapy had been com-
pleted for at least one month before the third evaluation,
but the other hormone replacement therapies were con-
tinuing (Levothyrox 75–100 microg/m2/d, hydrocorti-
sone 10 mg/m2/d, ethinyl estradiol or testosterone, see
below). The stimulations used at the third test were
arginine insulin (n = 9), glucagon (n = 7), or ornithine (n
= 5). Blood samples were obtained at 08.00 h for measur-
ing free thyroxin, cortisol, testosterone or estradiol. The
cortisol concentrations were not measured in the patients
on hydrocortisone replacement therapy. Plasma IGF I was
measured in all but 3 at diagnosis and in all at the third
evaluation.
The patients with gonadotropin deficiency had no puber-
tal development despite being of pubertal chronological
and bone ages and no gonadotropin response to a gona-
dotropin releasing hormone stimulation test. The girls
had been given oral ethinyl estradiol (2 microg/day) from
the age of around 12–13 years, and the boys testosterone
heptylate (25 mg i.m. every 14 days) from the age of
around 13–14 years.
Methods
Height was measured twice with a Harpenden stadiome-
ter. The height and body mass index (BMI, weight in kg/
height in m squared) are expressed as SDS for chronolog-
ical age [6,7]. Commercial immunoassays were used to
measure GH and IGF I (IGF-I-RIACT, Cis Bio, Gif sur
Yvette, France). GH was measured over the years using dif-
ferent immunoassays calibrated against different refer-
ence preparations. GH peaks were recalculated in order to
be expressed in ng/ml of the international reference stand-
ard 98/574 (recombinant 22 kDa GH, 1 ng = 3 microU).
The control group for plasma IGF I concentrations at the
first evaluation included normal prepubertal children,
and at the third evaluation it included 31 adolescents agedBMC Endocrine Disorders 2008, 8:7 http://www.biomedcentral.com/1472-6823/8/7
Page 3 of 6
(page number not for citation purposes)
14–16 years and 30 young adults aged 17–20 years with
normal height and weight and spontaneous pubertal
development [8].
Data are expressed as means ± SD. Groups were compared
with the Kruskall Wallis test followed by a Mann-Whitney
U tests and repeated measures were compared with the
Wilcoxon rank test.
Results
At diagnosis, all patients were prepubertal (Additional file
1). The oldest patients had bone ages of 11 years (case 9)
and 10 years (case 21). The 2 groups had similar chrono-
logical ages, heights, BMI, GH peaks after GHRH test,
plasma IGF I (expressed in SDS) and prolactin concentra-
tions (11.2 ± 8.4 vs 13.0 ± 7.8 ng/ml). Group 1 had signif-
icantly greater pituitary heights and GH peaks than did
group 2.
At the last evaluation, the group 1 patients had greater GH
peaks and more plasma IGF I (expressed both in ng/ml
and in SDS) than did those in group 2. No group 1 and 9
group 2 patients had an undetectable GH peak, while the
3 others had GH peak below 1 ng/ml. The two group 2
patients with IGF I concentrations similar to those of the
group 1 patients were girls (cases 18 and 19) with GH
peaks of 0.9 ng/ml and spontaneous puberty. The plasma
testosterone in boys and estradiol in girls at the third eval-
uation were pubertal in group 1 and low, but varying, in
the group 2 patients evaluated on low dose replacement
therapy.
The GH peaks and plasma IGF I concentrations (SDS)
were correlated at diagnosis (P < 0.04) and at the last eval-
uation (P < 0.001).
The GH peak decreased between diagnosis and the last
evaluation only in group 2 (P < 0.008, Table 1 and Fig 1).
Discussion
The GH peak response to pharmacological stimulation
and the plasma IGF I concentration in young adults with
GHD of childhood onset depend on the presence of addi-
tional pituitary deficiencies, reflecting a more severe
defect of the hypothalamic-pituitary axis. Sex steroids can-
not increase the IGF I if the GH secretion is zero.
The key features of this study are: 1) all the patients had
GHD due to PSIS of prepubertal onset; 2) each of them
was evaluated longitudinally before puberty and as a
young adult and the data from these evaluations were
compared.
1. Effect of the association with other pituitary deficiencies
The group 1 patients with isolated GHD had significantly
greater pituitary height and GH peaks at diagnosis before
puberty than did the group 2 patients with multiple defi-
ciencies, despite their similar ages, heights and BMI. This
may be due to differences in the way PSIS occurred in the
2 groups. We reported a positive correlation between the
GH peak after GHRH and the anterior pituitary height,
GH peak after no GHRH stimulation and the spontaneous
GH peak in patients with GHD (and PSIS in 22/28) [9].
While the GH peak after GHRH was greater in group 1
than in group 2 in the present study, the difference was
not significant, possibly because only three group 1
patients underwent the GHRH test.
This study confirms that the GH peak response to phar-
macological stimulation in GHD during childhood and in
young adults depends on the presence of additional defi-
ciencies. Maghnie et al [10] reported that all the 13
patients with PSIS tested as young adults had GH peak
responses to arginine, insulin and sequential tests that
were below 3 ng/ml, while 4 out of 21 patients of the
present study, all with isolated GHD, had a GH peak
greater than 3 ng/ml. Their findings and our results may
differ because more of our patients had isolated GHD.
Hartman et al [11] found that 41% of their adult patients
without pituitary hormone deficiencies other than GH
had a GH peak < 2.5 ng/ml, while 67% lacking one other
pituitary hormone, 83% of those lacking two pituitary
hormones, 96% of those lacking three pituitary hor-
mones, and 99% of those lacking four pituitary hormones
Table 1: Comparison between before and after GH treatment
Groups (n) Isolated GH deficiency (9) P Multiple pituitary deficiencies (12) P
at diagnosis at last evaluation at diagnosis at last evaluation
Height, SDS -3.0 ± 1.0 -1.0 ± 0.9 <0.008 -3.1 ± 1.6 -0.9 ± 0.7 <0.004
BMI, SDS -0.3 ± 1.2 0.6 ± 1.4 0.03 0.4 ± 2.4 0.6 ± 1.7 NS
GH peak, ng/ml 3.8 ± 1.9 3.9 ± 1.9 NS 1.6 ± 1.5a 0.2 ± 0.4b <0.008
IGF I, SDS -4.1 ± 0.9 -3.2 ± 1.2 NS -4.4 ± 0.9 -5.0 ± 0.9c NS
Testosterone, ng/ml 5.3 ± 1.8 1.7 ± 2.0
Mean ± SD
Isolated GH deficiency compared to multiple pituitary deficiencies: a: P < 0.02; b: P = 0.0001; c: P < 0.002BMC Endocrine Disorders 2008, 8:7 http://www.biomedcentral.com/1472-6823/8/7
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had a GH peak < 2.5 ng/ml. Their 3 patients with idio-
pathic GHD and a GH peak > 2.5 (2.9, 10 and 18) ng/ml
despite three deficiencies had GHD of adult onset and the
2 women were given oral estrogen.
2. Effect of sex steroids on GH-IGF I
The group 1 patients with spontaneous puberty showed
no increase in the GH peak in response to sex steroid
secretion, but the plasma IGF I concentrations (ng/ml)
did increase. The variations in the plasma estradiol or tes-
tosterone concentrations in the group 2 patients at the last
evaluation probably partly reflect differences in the inter-
val between the last administration of ethinyl estradiol or
testosterone and the GH evaluation in those with gonado-
tropin deficiency. Among the three group 2 patients with
spontaneous puberty, two had plasma IGF I concentra-
tions similar to those of group 1 patients, while the third
(case 12) had a very low plasma IGF I despite a plasma tes-
tosterone concentration of 5.6 ng/ml. They differed in
that their GH peak was greater than zero in the first two
(cases 18 and 19) and undetectable in the third patient
(case 12). This suggests that some residual GH secretion is
necessary for the sex steroids to increase IGF I. This prob-
ably explains the data reported by Aguiar-Oliveira et al
[12], who studied patients with a mutated GHRH receptor
that was responsible for a GH peak of 0.01–0.2 ng/ml.
They were surprised to find that there was no significant
pubertal rise in IGF I, IGF II, IGF binding protein-3, or
acid-labile subunit concentrations, as pubertal develop-
ment was normal, although slightly delayed.
The administration of high doses of sex steroids before the
last evaluation to the patients with gonadotropin defi-
ciency, to obtain levels similar to those of group 1, would
Data for each of 21 patients with GH deficiency with pituitary stalk interruption syndrome at diagnosis and after GH treatment  classified according to whether there was isolated GHD (n = 9) or multiple Figure 1
Data for each of 21 patients with GH deficiency with pituitary stalk interruption syndrome at diagnosis and after GH treatment 
classified according to whether there was isolated GHD (n = 9) or multiple.
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help to confirm the absence of a direct affect of sex ster-
oids on IGF I. However, one patient from group 1 (case 3)
and two from group 2 (cases 10 and 15) with similar
plasma testosterone concentrations (spontaneously or
after administration) but different GH peaks (3 and 0 ng/
ml) had different plasma IGF I concentrations (296 vs 59
and 78 ng/ml). Martinez et al [13] evaluated the effect of
estradiol priming on the GH-IGF axis in 15 patients with
GHD and radiological findings after magnetic resonance
imaging. They were given a daily dose of 1 or 2 mg micro-
nized estradiol or placebo for 3 days before a sequential
arginine-clonidine test. Estradiol did not significantly
stimulate GH secretion (3.1 ± 2.4 vs 4.5 ± 2.7 ng/ml). The
IGF I concentrations of 14/15 patients on placebo were
below normal and estradiol did not change the mean of
the group (28 ± 48 vs 25 ± 29 ng/ml).
3. Diagnosis of GHD in adults
The key feature of this study is that all the patients had
GHD due to PSIS of prepubertal onset. The majority of the
patients with adult-onset GHD had had a hypothalamic-
pituitary lesion and had been treated by surgery and/or
irradiation. Their results are consistent with previous find-
ing that patients with craniopharyngioma [8,14] or given
low dose cranial irradiation [4] may have a normal
plasma IGF I concentration. This may partly explain why
Hoffman et al [15] found that 70% of the IGF I and 72%
of the IGF binding protein-3 concentrations were within
the normal range in adults with a GH peak below 5 ng/ml
after an insulin test (pituitary adenoma or cranial irradia-
tion) while de Boer et al [16] found only 4% of the IGF I
and 8% of the IGF binding protein-3 concentrations were
normal in young adults with idiopathic GHD of child-
hood onset.
Our results partly explain the difficulty of defining a lim-
iting plasma IGF I concentration for diagnosing GHD in
adults. Hartman et al [11] concluded that patients with an
appropriate clinical history and having 3 or 4 additional
hormonal deficiencies or a serum IGF I less than 84 ng/ml
do not require a GH stimulation test for the diagnosis of
adult GHD. We found that IGF I was very low in all
patients with gonadotropin deficiency, and in the sole
patient with spontaneous puberty but a GH peak of 0 ng/
ml.
4. Analysis of the limitations of the study
The number of subjects studied is limited, but there are no
reported data on the longitudinal evolution in GH and
IGF I in patients with PSIS and only limited data on
patients with PSIS in the transition period [17]. These
authors used the GHRH plus arginine test. In the present
study, the GH peaks for a given patient obtained during
childhood and as a young adult were not obtained using
similar stimulations, but arginine insulin or glucagon
were used as stimulus in the majority of patients. The
short time between stopping GH and testing our patients
may partly explain the concentrations of IGF I. Thus,
Maghnie et al [10] reported that the IGF I concentrations
decreased significantly 6 and 12 months after stopping
GH in patients with PSIS. However, the interval was
greater than one month in all. Group 2 patients had low
plasma IGF I concentrations, whatever the interval. A
recent Endocrine Society Clinical Practice Guideline [18]
suggested that the interval between the reevaluation and
the discontinuation of GH treatment should not be less
than one month, and because of the irreversible nature of
GHD in children with PSIS and multiple hormonal defi-
ciencies, a low IGF I measured at least one month after
discontinuing treatment is sufficient documentation of
persistant GHD without additional provocative testing.
Our data confirm this statement.
Conclusion
The GH peak response to pharmacological stimulation
and the plasma IGF I concentration in young adults with
GHD of childhood onset and PSIS depend on the pres-
ence of additional pituitary deficiencies, reflecting a more
severe defect of the hypothalamic-pituitary axis. This
severity can also be assessed by the height of the anterior
pituitary gland on magnetic resonance imaging and by the
GH response to a GHRH test.
Thus diagnosis of GHD in the transition period must take
into account the presence or absence of other pituitary
deficiencies. The GH peak may be greater than 3 ng/ml
and the plasma IGF I greater than 84 ng/ml if the GH def-
icit is isolated.
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